AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

Hinterhaus Productions
AbbVie (ABBV) has agreed to pay up to $2.54B to collaborate with Germany-based biotech DISCO Pharmaceuticals on the development of novel cancer treatments, marking an early-stage expansion of the drugmaker's efforts in next-generation bispecific therapies.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.